Get the Weekly Intelligence Brief — top committee picks every Sunday.
NASDAQ · STOCK

Johnson & Johnson

JNJ Healthcare Unknown Updated July 31, 2026
$256.46
52W $164.79 – $274.90
55/100
$617.78B
29.6
0.23
AI Committee Verdict
Watch
Conviction: Contested · 43% agreement · 7 analysts
-14.1%
Contested

Is JNJ Bullish or Bearish?

Mixed. Innellis AI committee rates Johnson & Johnson (JNJ) Watch with a composite score of 55/100 , based on 7 analysts with 43% agreement. Last updated July 31, 2026.

What Would Change This View

Upgrade to Buy
Requires a committee score of 60.0 — +5.11 from today. Applies on the first day at or above the line; upgrades are never dampened.
Downgrade to Reduce
Requires the score to fall below 40.0 — -14.89 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.

Executive Summary

The committee is genuinely divided. News Analyst sees a compelling case — news sentiment is positive (+0.40 across 200 articles, 14d). Growth Analyst remains cautious — eps declining -7.8% yoy despite any revenue growth. This disagreement is itself the signal — the setup is not clean in either direction.

Bull & Bear Case

Bull Case
  • ROE of 25.7% shows genuine earnings power backing the valuation — Value
  • Price structure making higher highs and higher lows — Technical
  • Trend and market structure agree -- coherent bullish picture — Technical
  • Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
  • Market regime is bullish (Bull market -- normal position sizing) — Macro
  • News sentiment is positive (+0.40 across 200 articles, 14d) — News
Bear Case
  • P/E of 29.5 is moderate-to-rich — Value
  • Price-to-book of 6.1x prices in significant intangible value — Value
  • EPS declining -7.8% YoY despite any revenue growth — Growth
  • Growth rate is decelerating quarter over quarter -- the trend line matters more than the level — Growth
  • MACD histogram negative -- bearish momentum — Technical
Both cases are generated from quantitative data signals, not qualitative or forward-looking judgement. They summarise what the numbers say today.
Price History (6M)

AI Investment Committee

Committee Consensus As of July 31, 2026
Overall Committee Score
55/100
Agreement
43%
Analysts
7
Conviction
Contested
Sector Rank
Top 57%
of 93 Healthcare peers
Value Analyst neutral
48 / 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
+ ROE of 25.7% shows genuine earnings power backing the valuation
− P/E of 29.5 is moderate-to-rich
Growth Analyst bearish
32 / 100 · High confidence
Growth story is weak, decelerating, or inconsistent
− EPS declining -7.8% YoY despite any revenue growth
Technical Analyst bullish
61 / 100 · High confidence
Price action is constructive -- trend and momentum agree
+ Price structure making higher highs and higher lows
− MACD histogram negative -- bearish momentum
Risk Analyst bullish
70 / 100 · Low confidence
Risk profile is manageable -- leverage, volatility, and event exposure all look contained
Macro Analyst neutral
58 / 100 · Moderate confidence
Macro backdrop is mixed or neutral -- not a strong tailwind or headwind either way
+ Market regime is bullish (Bull market -- normal position sizing)
News Analyst bullish
70 / 100 · Low confidence
News flow and recent filings/analyst actions are net positive
+ News sentiment is positive (+0.40 across 200 articles, 14d)
Portfolio Manager neutral
45 / 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 2744.14)
Open Full Terminal →

Investment Thesis Evolution

Committee score strengthened from 51.6 to 54.9.

Analyst-level changes:
  • Macro Analyst: stance bullish->neutral; score 65->58 (-8); +1 bullish signal(s).
  • News Analyst: stance neutral->bullish; score 51->70 (+20); +1 bullish signal(s).
  • Portfolio Manager: +2 bearish signal(s).
  • Risk Analyst joined: bullish at 70.
  • Technical Analyst: score 69->61 (-8); +1 bearish signal(s).
  • Value Analyst: +1 bearish signal(s).

Comparing 2026-07-30 to 2026-07-31 (1 day apart).

Technical Analysis

RSI (14)
46.4
Neutral
MACD Histogram
-0.503
Bearish Momentum
Trend Direction
Uptrend
Weekly: Uptrend
Market Structure
Hh Hl
Bollinger %B
0.45
Inside Bands
Price vs Moving Averages
EMA 9
$259.23 Below
EMA 21
$256.11 Above
EMA 50
$248.59 Above
EMA 200
$225.98 Above

Fundamental Analysis

Valuation
50
Growth
62
Profitability
1
Financial Health
60
Cash Flow
37
Valuation
P/E Ratio 29.6×
P/B Ratio 7.36×
PEG Ratio -3.67
Dividend Yield 0.02%
52W High $274.90
52W Low $164.79
Quality & Growth
ROE 32.9%
ROA 13.5%
Gross Margin 70.5%
Operating Margin 26.8%
Revenue Growth YoY
Debt / Equity 0.58
AI Fundamental Assessment
P/E ratio of 29.6 (moderate relative to a 15-40x range); Price-to-book of 7.4x; PEG ratio of -3.7 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 0.3%; Return on assets of 0.1%; Net margin of 0.2%; Gross margin of 0.7%; Current ratio of 1.09 (tight short-term liquidity); Debt-to-equity of 0.58; Free cash flow margin of 0.8% (thin cash generation); Free cash flow per share is positive (7.67); Most recent quarter beat estimates by 0.9%; 2 consecutive earnings beats; EPS growth decelerating (+9.8% -> +7.4% QoQ); Average YoY EPS growth of 4.7%; Analyst estimates rising over recent quarters
Get the Full JNJ Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →

Explore JNJ Further

📈 Rating History 💰 Earnings 📰 Recent Events 🔄 What Changed 📖 Thesis Evolution 🔍 Similar Stocks
Weekly Intelligence Brief
Get the committee's top-scored stocks every Sunday.
Free · No spam · Unsubscribe anytime